Agenus shared on LinkedIn:
“Today at IGCS 2026, we presented three-year follow-up data from our Phase 1b study of BOT+BAL in recurrent ovarian cancer.
Estimated overall survival was 48% at three years, unchanged from the two-year estimate, highlighting the durability of survival observed in this heavily pretreated, difficult-to-treat population.
Learn more in our press release.”
Other articles about ovarian cancer on OncoDaily.